Imondi A R, Alam A S, Brennan J J, Hagerman L M
Arch Int Pharmacodyn Ther. 1978 Mar;232(1):79-91.
The metabolism of 14C-carbonyl-sulpiride (form A) and of 14C-3, 4 pyrrolidine-sulpiride (form B) was studied in the rhesus monkey and man. In the monkey, the metabolites in both the urine and the bile were the same with form A and form B: 60-80% sulpiride, 10-30% 5-oxopyrrolidine sulpiride and 3-8% an unidentified metabolite (ME-X). In four human volunteers given a single oral dose of either 108 mg form A or 100 mg form B, more than 95% of the 14C recovered in the urine and feces was unchanged sulpiride. Sulpiride levels in plasma reached maximum in 3 hr and ranged from 232 to 403 ng/ml. The plasma t1/2 was 8.3 hr. Pharmacokinetic analyses indicated little or no biliary excretion of sulpiride in man.
在恒河猴和人类中研究了14C-羰基舒必利(A 型)和14C-3,4-吡咯烷舒必利(B 型)的代谢情况。在猴子中,尿液和胆汁中的代谢产物对于 A 型和 B 型是相同的:60-80%为舒必利,10-30%为5-氧代吡咯烷舒必利,3-8%为一种未鉴定的代谢产物(ME-X)。在四名单次口服108 mg A 型或100 mg B 型的人类志愿者中,尿液和粪便中回收的14C 超过95%为未变化的舒必利。血浆中舒必利水平在3小时达到峰值,范围为232至403 ng/ml。血浆半衰期为8.3小时。药代动力学分析表明,在人类中舒必利很少或没有经胆汁排泄。